WAKLERT 150

What is WAKLERT 150?

WAKLERT 150 is a modern pharmaceutical drug in the form of tablets for oral administration, containing the active pharmaceutical ingredient armodafinil at a dosage of 150 mg. It belongs to the pharmacotherapeutic group of psychostimulants and nootropics used to correct sleep-wake cycle disorders. The drug is manufactured by the Indian pharmaceutical company Sun Pharma Laboratories, one of the global leaders in the production of high-quality generics. The main purpose of WAKLERT 150 is to maintain a state of wakefulness and increase cognitive performance in individuals with excessive daytime sleepiness. Unlike classic stimulants, armodafinil acts more selectively, reducing the risk of developing severe tachycardia or euphoria. Due to this, WAKLERT 150 is considered the drug of choice for long-term therapy of wakefulness disorders in adult patients.

Armodafinil, contained in WAKLERT 150, is the R-enantiomer of modafinil — a substance that has long been used in global medical practice. This molecular form has a longer elimination half-life and a more stable plasma concentration compared to conventional modafinil. That is why the effect of taking WAKLERT 150 develops gradually and is maintained throughout the day without sharp peaks of activity. The drug is not a classic amphetamine-like psychostimulant, although its action is aimed at activating the central nervous system. It affects specific regions of the hypothalamus responsible for regulating wakefulness, providing a more physiological profile of action. WAKLERT 150 is dispensed by prescription only and requires a prior examination to rule out other causes of sleepiness.

In clinical practice, WAKLERT 150 has proven to be a reliable agent for improving the quality of life of patients with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Its use allows for a reduction in the number of sudden sleep episodes and an increase in concentration during daily tasks. It is important to understand that WAKLERT 150 does not cure the underlying condition, but only manages its symptoms, which is why therapy must be comprehensive. The drug is well tolerated by most patients; however, it requires strict adherence to the recommended dosage regimen. Before starting the course, a consultation with a sleep specialist or neurologist is mandatory to evaluate the benefit/risk ratio. Self-medication with WAKLERT 150 is unacceptable, as improper use can trigger adverse cardiovascular reactions.

What is WAKLERT 150 prescribed for?

The main indications for the use of WAKLERT 150 are conditions accompanied by pathological daytime sleepiness, which significantly reduces work capacity and social activity. Most often, the drug is prescribed to patients with a confirmed diagnosis of narcolepsy — a chronic neurological disorder characterized by sudden sleep attacks and cataplexy. In such cases, WAKLERT 150 helps maintain a stable level of wakefulness throughout the day, preventing uncontrolled falling asleep in dangerous situations, such as while driving. The therapeutic effect develops gradually, so patients are advised to take it regularly according to the prescribed regimen. Clinical studies confirm a significant improvement in attention span and reaction speed after just the first week of treatment.

The second important group of indications is obstructive sleep apnea syndrome, where nocturnal breathing pauses lead to chronic sleep deprivation and severe daytime fatigue. WAKLERT 150 is prescribed as an adjunctive treatment to primary therapy (CPAP therapy or surgical treatment) if sleepiness persists despite the elimination of obstruction. The drug allows patients to remain active during the workday and reduces the risk of emergency situations associated with falling asleep. WAKLERT 150 is also effective for shift work sleep disorder, when a person is forced to work at night or on a rotating schedule. In such cases, the agent helps adapt the biological clock to an unconventional schedule and maintains cognitive functions at a proper level. Importantly, the drug does not replace full sleep, but only temporarily masks its deficit.

In certain clinical situations, WAKLERT 150 may be recommended for idiopathic hypersomnia — a condition where the cause of excessive sleepiness remains undetermined after a complete medical evaluation. The drug is also sometimes used in the comprehensive therapy of depressive disorders accompanied by severe asthenia and reduced energy; however, such use is off-label and requires special caution. It should be remembered that WAKLERT 150 is not intended for treating ordinary fatigue in healthy individuals or for boosting academic performance. Its use without medical indications can lead to the development of tolerance and psychological dependence. A physician determines the appropriateness of prescribing the drug only after a careful history collection and polysomnography. Patients with cardiovascular diseases must undergo an additional cardiological examination before starting therapy.

Composition and active components of WAKLERT 150

Each WAKLERT 150 tablet contains 150 mg of armodafinil — the active R-enantiomer of modafinil, which is the main active ingredient of the drug. Armodafinil is a white to off-white crystalline powder, practically insoluble in water, which accounts for its specific pharmacokinetic properties. After oral administration, the substance is rapidly absorbed in the gastrointestinal tract, reaching peak plasma concentration in approximately 2 hours. The elimination half-life of armodafinil is about 15 hours, providing a long-lasting effect of the drug throughout the day. Unlike modafinil, armodafinil has a more predictable pharmacological profile and less variability in blood concentrations. This allows for achieving a stable therapeutic effect with a single daily dose.

Excipients of WAKLERT 150 include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate. These substances act as fillers, binders, and lubricants, ensuring proper tablet stability and disintegration in the gastrointestinal tract. Lactose monohydrate gives the tablet the necessary mass and hardness, while croscarmellose sodium promotes rapid release of the active ingredient after swallowing. Patients with lactose intolerance should take the presence of this component into account and discuss the possibility of using alternative forms with their doctor. Magnesium stearate is used as an anti-adherent agent to prevent the powder mass from sticking to equipment during manufacturing. All excipients are of pharmacopeial quality and meet international safety standards.

The mechanism of action of armodafinil is associated with the selective activation of dopaminergic and noradrenergic systems in the brain, particularly in the hypothalamus and prefrontal cortex. The drug blocks dopamine reuptake, increasing its concentration in the synaptic cleft, which helps maintain a state of wakefulness. Simultaneously, armodafinil modulates the activity of the orexin system, which plays a key role in regulating the sleep-wake cycle. Unlike traditional psychostimulants, WAKLERT 150 does not cause a significant release of dopamine from presynaptic vesicles, reducing the risk of euphoria and addiction. This selective mechanism of action provides mild stimulation of the central nervous system without pronounced sympathomimetic effects. This makes the drug suitable for long-term use in patients with chronic sleep disorders.

Dosage of WAKLERT 150

The standard recommended dose of WAKLERT 150 for adult patients is 150 mg once daily, preferably in the morning or 1 hour before the start of a work shift. For patients with narcolepsy or obstructive sleep apnea, the drug is usually taken in the morning to ensure wakefulness throughout the day. In the case of shift work sleep disorder, WAKLERT 150 is taken approximately 1 hour before beginning the night shift, allowing concentration to be maintained during the period of maximum sleepiness. The maximum daily dose should not exceed 250 mg; however, increasing the dosage is possible only as prescribed by a doctor and under their supervision. Increasing the dose on one's own does not lead to a proportional increase in effect, but significantly increases the risk of side effects. The duration of therapy is determined individually depending on clinical response and drug tolerance.

For elderly patients (over 65 years old), dose adjustment is usually not required; however, it is recommended to start treatment with the minimum effective dose and carefully monitor liver and kidney function. In patients with severe hepatic impairment, the dose of WAKLERT 150 should be reduced by half, as metabolism of the drug occurs predominantly in the liver. In mild to moderate renal impairment, dose adjustment is not necessary, but patients with end-stage renal disease require special caution. WAKLERT 150 is not recommended for use in children and adolescents under 18 years of age due to the lack of sufficient safety and efficacy data. If a patient misses a dose, they should not double the next dose, as this may cause excessive stimulation and disturbance of night sleep. It is best to take the missed dose as soon as possible, but if less than 6 hours remain until the next dose, the missed dose should be skipped.

The duration of the WAKLERT 150 treatment course depends on the underlying condition and individual patient response. In narcolepsy and idiopathic hypersomnia, therapy may be long-term, sometimes lifelong, with periodic breaks to assess the need for continued treatment. In the case of shift work sleep disorder, the drug is used only on days when the patient works night shifts, which helps avoid the development of tolerance. A doctor may recommend a gradual dose reduction before complete discontinuation, especially if therapy has lasted for more than 3 months. Abrupt cessation of WAKLERT 150 is usually not accompanied by severe withdrawal syndrome, but a temporary return of sleepiness symptoms is possible. To achieve an optimal therapeutic effect, it is important to adhere to a regular dosing schedule and not miss prescribed doses without consulting a physician.

How to properly take WAKLERT 150?

WAKLERT 150 should be taken orally, swallowed with a sufficient amount of water, regardless of food intake. However, it should be noted that consuming high-fat food can delay the absorption of the drug and delay the onset of the therapeutic effect by approximately 1–2 hours. Therefore, to achieve faster results, it is recommended to take the tablet on an empty stomach or after a light breakfast. The tablet should not be chewed, crushed, or divided, as this may disrupt the integrity of the enteric coating and alter the pharmacokinetics of the drug. WAKLERT 150 is intended for single daily administration, so it is important to choose a convenient time that will avoid disturbing nighttime sleep. Taking the drug later than 2:00 PM may cause insomnia and difficulty falling asleep in patients with a sensitive nervous system.

If a patient forgets to take WAKLERT 150 at the usual time, they should take the medication as soon as they remember, provided that at least 8 hours remain until the next scheduled dose. If there is a significant delay, it is better to skip the dose and return to the normal schedule the next day to avoid a cumulative effect. During WAKLERT 150 therapy, patients are advised to maintain a regular sleep schedule and avoid chronic sleep deprivation, as the drug does not replace physiological rest. It is also important to limit the intake of caffeinated beverages, as combining them with armodafinil can exacerbate anxiety, tachycardia, and tremors. Patients with arterial hypertension should regularly monitor their blood pressure, especially during the first weeks of treatment. The onset of severe headache, nausea, or palpitations is a reason to consult a doctor.

While taking WAKLERT 150, one should abstain from alcohol consumption, as ethanol can worsen side effects affecting the central nervous system and liver. The drug can reduce the effectiveness of hormonal contraceptives; therefore, women of childbearing potential are advised to use additional barrier methods of protection during therapy and for one month after its completion. WAKLERT 150 can impair the ability to drive vehicles and operate complex machinery, especially at the start of treatment, when dizziness or impaired concentration may occur. Patients should evaluate their individual response to the drug before driving or engaging in potentially hazardous activities. In case of any doubts regarding the safety of WAKLERT 150, consulting a doctor or pharmacist is necessary. Following these guidelines helps minimize risks and achieve maximum therapeutic effect.

Side effects of WAKLERT 150

The most common side effects of WAKLERT 150 are headache, nausea, dry mouth, loss of appetite, and insomnia. These symptoms usually occur at the start of therapy and tend to diminish during the first 1–2 weeks of treatment. Headaches associated with the drug are most often mild or moderate and respond well to standard analgesics. Nausea and dyspeptic symptoms can be minimized by taking the tablet after meals or with a small amount of food. Reduced appetite is an expected effect, so patients with low body weight should monitor their caloric intake. Insomnia occurs primarily when the dosing regimen is violated, particularly when taking the drug in the afternoon.

Less common adverse reactions of WAKLERT 150 include tachycardia, elevated blood pressure, anxiety, irritability, and tremors. In patients with cardiovascular diseases, these symptoms may be more pronounced and require dose adjustment or drug discontinuation. Skin reactions such as rash, itching, or urticaria are possible and usually resolve after stopping administration. Rare but serious side effects include Stevens-Johnson syndrome and toxic epidermal necrolysis, which require immediate medical attention. The appearance of chest pain, severe shortness of breath, edema, or fainting is a reason for urgent medical care. Patients with a history of psychiatric disorders should pay close attention to mood changes, hallucinations, or suicidal thoughts.

An individual's reaction to WAKLERT 150 can vary significantly depending on age, sex, genetic metabolic characteristics, and concomitant conditions. Some patients may experience excessive stimulation even at a minimal dose, while others require a dosage increase to achieve a clinical effect. If any unusual symptoms occur that the patient links to taking the drug, treatment should be discontinued and medical advice sought. A doctor may order additional tests to rule out serious complications or adjust the therapy. It is important to inform the doctor about all medications the patient is taking concurrently, as this helps prevent unwanted interactions. Regular health monitoring during WAKLERT 150 therapy is the key to safe and effective treatment.

Contraindications of WAKLERT 150

An absolute contraindication to the use of WAKLERT 150 is hypersensitivity to armodafinil, modafinil, or any excipient of the drug. Patients with a known allergy to lactose or other tablet components should avoid taking this medication. The drug is contraindicated in severe arterial hypertension, uncontrolled arrhythmias, and other serious cardiovascular diseases, as the stimulating effect can trigger an exacerbation. WAKLERT 150 is not prescribed to patients with hypertrophic cardiomyopathy and mitral valve prolapse with significant regurgitation. The presence of psychotic disorders, such as schizophrenia or bipolar affective disorder, is also a contraindication due to the risk of worsening psychotic symptoms. In patients with severe hepatic impairment, the drug is prescribed with great caution and in reduced doses.

WAKLERT 150 is not recommended for use during pregnancy, as data on the safety of armodafinil for the fetus are limited. Animal studies have shown a potential teratogenic effect, so women of childbearing potential should use reliable contraception during therapy. The drug passes into breast milk, so breastfeeding should be discontinued for the period of treatment. WAKLERT 150 is not prescribed to children and adolescents under 18 years of age due to the lack of sufficient clinical data on efficacy and safety. The drug may be prescribed to elderly patients, but with caution and under monitoring of liver, kidney, and cardiovascular functions. For individuals with a history of drug or alcohol dependence, WAKLERT 150 should be prescribed strictly according to indications due to the potential risk of abuse.

Relative contraindications include epilepsy and seizure disorders, as the psychostimulatory effect can lower the seizure threshold. In patients with anxiety disorders, panic attacks, or severe insomnia, the drug is prescribed with caution, as these symptoms may intensify. The presence of active peptic ulcer disease of the stomach and duodenum is also a relative contraindication due to a possible irritant effect on the mucosa. Before starting WAKLERT 150 therapy, a physician must carefully take a history and assess all potential risks. For patients with severe renal impairment, a dose reduction and regular monitoring of creatinine clearance are recommended. In case of any doubts regarding the safety of the drug's use, additional specialist consultation is required.

Interaction of WAKLERT 150 with other drugs and alcohol

WAKLERT 150 can interact with a number of medications, which requires special attention during combination therapy. Armodafinil is an inducer of cytochrome P450 enzymes, particularly CYP3A4; therefore, it can accelerate the metabolism of many drugs, reducing their effectiveness. This applies to hormonal contraceptives, cyclosporine, midazolam, triazolam, and certain antiretroviral agents. Women taking oral contraceptives should use additional methods of protection during WAKLERT 150 therapy and for one month after its completion. Concomitant use with warfarin requires regular monitoring of the International Normalized Ratio (INR), as a decrease in the anticoagulant effect is possible. Patients taking antiepileptic drugs should monitor their blood concentrations, as armodafinil can reduce their levels.

Combining WAKLERT 150 with alcohol is not recommended, as ethanol can increase toxic effects on the liver and central nervous system. Alcohol can mask or, conversely, intensify the side effects of the drug, including dizziness, impaired coordination, and drowsiness. Furthermore, consuming alcohol during therapy can reduce the efficacy of WAKLERT 150 and contribute to unpredictable reactions. The drug can affect the ability to drive vehicles, so patients should refrain from driving until their individual reaction is clarified. Simultaneous intake with other stimulants, such as high doses of caffeine, can cause excessive nervousness, tachycardia, and tremor. Patients with cardiovascular diseases should avoid combining WAKLERT 150 with sympathomimetics and other medications that raise blood pressure.

Where to buy WAKLERT 150 in Ukraine

WAKLERT 150 is a prescription drug, so its purchase is possible only with a valid prescription from a doctor. In Ukraine, the drug is available in specialized pharmacy chains that cooperate with suppliers of imported medicines. Patients are advised to contact verified pharmacies licensed to sell prescription drugs that can provide quality certificates. The cost of WAKLERT 150 may vary depending on the region, pharmacy chain, and currency exchange rate, as the drug is imported from India. Before purchasing, check the integrity of the packaging, expiration date, and the presence of protective marking confirming the product's authenticity. It is not recommended to buy the drug from questionable online stores or individuals without a pharmaceutical license, as this carries the risk of receiving counterfeit products.

WAKLERT 150 should be stored in a dry place, protected from light, at a temperature not exceeding 25 °C, out of the reach of children. The shelf life of the drug is usually 2 years from the date of manufacture, after which use is prohibited. Some pharmacy chains offer an online reservation service followed by receiving the drug at a physical pharmacy upon presentation of a prescription. Patients should check the availability of WAKLERT 150 in a specific pharmacy in advance, as the drug is not always widely available. Before starting therapy, a consultation with a physician is mandatory to determine the appropriateness of the drug's use and provide dosing recommendations. Individual body reaction to WAKLERT 150 may vary, so self-medication and uncontrolled intake are unacceptable.